Brief: Veracyte Says New Data Show Use Of The Prosigna Test Significantly Changed Treatment Decisions For Patients With Early-Stage Breast Cancer
12/05/2023 12:19
May 12 (Reuters) - Veracyte Inc VCYT.O :
* VERACYTE ANNOUNCES THAT NEW DATA SHOW USE OF THE PROSIGNA
TEST
SIGNIFICANTLY CHANGED TREATMENT DECISIONS FOR PATIENTS WITH
EARLY-STAGE BREAST CANCER
Source text for Eikon: ID:nBw5PGLKqa
Further company coverage: VCYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina